title: A second look at efficacy criteria for onychomycosis: clinical and mycological cure.
abstract: BACKGROUND
  Approval of topical onychomycosis drugs by regulatory agencies may be negatively impacted by an overly stringent definition of complete cure, which includes nail clearing plus mycological cure.
  
  
  OBJECTIVE
  In this position paper, we discuss interpretation of mycological outcome and clinical trial length.
  
  
  METHODS
  We reviewed data from seven international onychomycosis trials that enrolled subjects with positive KOH and dermatophyte-positive culture at screening followed by 48 weeks of treatment. Further, we examined 94 KOH-positive/culture-negative week 52 follow-up samples for morphological hyphal damage.
  
  
  RESULTS
  From 3054 samples collected at week 52 follow-up visits, 2360 were culture-negative. However, a significant percentage (78.7%) of these subungual samples (n = 1857) remained KOH-positive. From the subset of follow-up samples examined for morphological changes, we identified hyphal breakage or distortion in 56 direct smears (60%), which may indicate nonviability.
  
  
  CONCLUSIONS
  Reassessment of the definition of onychomycosis cure is critical. For clinical trials of topical agents, length of treatment should be re-examined. Further, in our experience, a high rate of subungual debris samples remained direct smear-positive while converting to negative culture. Evidence of morphological hyphal damage suggests that late-visit microscopic results may be false-positives. Therefore, the absence of clinical signs following an adequate washout period, coupled with a negative culture, with or without negative microscopy, should be considered the definition of onychomycosis cure.
authors: Center for Medical Mycology, Department of Dermatology, University Hospitals Case Medical Center, Cleveland, OH, U.S.A.
authors: M
authors: M
authors: Ghannoum
authors: N
authors: N
authors: Isham
authors: V
authors: V
authors: Catalano
mesh_terms: D000287:Administration, Topical; D000935:Antifungal Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D014009:Onychomycosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents